A patient with Cushing disease lateralizing a pituitary adenoma by inferior petrosal sinus sampling using desmopressin: a case report by 沅뚯븘由� et al.
A patient with Cushing disease lateralizing a 
pituitary adenoma by inferior petrosal sinus 
sampling using desmopressin: a case report
Case report
A 14-year-old girl was referred for evaluation of the etiology of Cushing syndrome. 
During the previous 2 years, she had experienced weight gain, secondary 
amenorrhea, growth retardation, and back pain. Random serum cortisol level, 24-
hour urinary free cortisol excretion, and overnight and low-dose dexamethasone 
suppression tests suggested Cushing syndrome. Midnight adrenocorticotropic 
hormone (ACTH) level and high-dose dexamethasone suppression test confirmed 
Cushing disease. Pituitary magnetic resonance imaging was suspicious for 
microadenoma. To eliminate ectopic ACTH syndrome, and lateralize the pituitary 
tumor, inferior petrosal sinus sampling (IPSS) was performed by desmopressin use 
to stimulate ACTH. Finally, the patient was diagnosed with Cushing disease due to 
ACTH-secreting pituitary microadenoma, lateralized to the left side; subsequently 
underwent transsphenoidal surgery. Here we report a case of a 14-year-old girl 
diagnosed with Cushing disease with a pituitary tumor lateralized by IPSS using 
desmopressin, which is very rare in pediatric Cushing disease.
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Introduction
Cushing syndrome is caused by excessive circulating glucocorticoid concentrations caused 
by endogenous secretion or exogenous administration (iatrogenic Cushing syndrome)1). 
Endogenous Cushing syndrome is subdivided according to adrenocorticotropic hormone 
(ACTH) dependency. ACTH-dependent Cushing syndrome is due to ACTH-secreting 
pituitary adenomas (Cushing disease), ectopic ACTH-secreting tumors, and ectopic cortico-
tropin-releasing hormone (CRH) syndrome1). A precise differential diagnosis of Cushing 
syndrome is often difficult due to the overlapping symptoms and signs among these subtypes. 
In particular, differential diagnosis between Cushing disease and ectopic ACTH-secreting 
tumors is difficult, even though there are helpful biochemical diagnostic tests or imaging 
studies such as magnetic resonance imaging (MRI) or scintigraphy2). A pituitary MRI should 
be performed in all patients to diagnose ACTH-dependent Cushing disease, but this fails to 
identify the exact tumor origin and site in up to 50% of patients3). Therefore, inferior petrosal 
sinus sampling (IPSS) is considered the gold standard for identifying both the origin of tumors 
and the site of a pituitary adenoma4).
IPSS is a method that compares the blood level of ACTH collected from peripheral vessels 
and both sides of the inferior petrosal sinus after stimulation of ACTH secretion with CRH 
administration5). Since 1995, desmopressin has been used in place of CRH due to the limited 
supply of CRH6). Approximately 150 patients with Cushing disease tested with desmopressin 
have been reported on so far with the results showing sensitivity comparable to that of CRH 
stimulation4). However, bilateral IPSS and use of desmopressin is uncommon in children, 
and there are few reports of the accuracy and complications of IPSS using desmopressin in 
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children. We report the case of a 14-year-old girl successfully 
diagnosed with Cushing disease lateralized by IPSS with 
desmopressin. 
Case report
A 14-year-old girl was referred to the Pediatric Endocrinology 
Clinic of Severance Children's Hospital for evaluation of the 
etiology of Cushing syndrome. In the 2 years prior to referral, 
the patient had experienced weight gain (20 kg/2 years), secon-
dary amenorrhea, growth retardation, and back pain. Despite 
chiropractic adjustment for back pain, symptoms worsened 
and she was admitted to a tertiary hospital for conservative care 
and evaluation. During the diagnostic examination, spine MRI 
showed a compression fracture with osteoporosis, and further 
evaluations for osteoporosis and amenorrhea were performed. 
A random cortisol level (38.4 µg/dL) and 24-hour urinary free 
cortisol (UFC, 1280.0 μg/day; normal reference value, 10–34 μg/
day) were elevated, suspecting Chshing's syndrome (Table 1). 
Serum cortisol levels at 8 AM after an overnight dexamethasone 
suppression test (1 mg once) and low-dose dexamethasone 
suppression test (0.5 mg every 6 hours for 2 days) were not 
adequately suppressed (30.0 µg/dL and 11.9 µg/dL, respectively; 
normal reference value, <1.8 µg/dL), which confirmed Cushing 
syndrome (Table 1). A midnight ACTH level was 32 pg/mL, 
which is greater than 22 pg/mL, confirming that the underlying 
disease was ACTH-dependent. A subsequent high-dose 
dexamethasone suppression test (2 mg every 6 hours for 2 days) 
to confirm Cushing disease was performed. Serum cortisol 
(8.3 µg/dL) and 24-hour UFC (251.0 µg/day) were suppressed 
by more than 50% compared to baseline, supporting a definite 
diagnosis of Cushing disease (Table 1). However, pituitary 
MRI failed to identify a lesion and the patient was referred to 
our institute for further evaluation of the etiology of Cushing 
syndrome .
On admission, the patient's height and weight were 142 
cm (<3rd percentile) and 53.5 kg (50th–75th percentile), and 
her BMI was 26.58 kg/m2. Hypertension (149/109 mmHg) 
was observed with a normal heart rate (96 beats/min), body 
temperature (36.9℃), and respiratory rate (16 breaths/min). 
She appeared chronically ill, with diffusely thin, wrinkled skin 
with plethora. She displayed a moon-shaped face (Fig. 1A), a 
buffalo hump (Fig. 1B), truncal obesity, acanthosis nigricans, 
and abdominal striae (Fig. 1C). 
As her previous test results strongly suggested Cushing 
disease rather than an ectopic ACTH-producing tumor, a 
thin-slice pituitary MRI was performed. The MRI showed a 
heterogeneous enhancing lesion (approximately 6 mm) in 
the midline area of posterior aspect of the pituitary fossa, and 
pituitary microadenoma was suspected (Fig. 2A, B). A positron 
emission tomography study also found diffuse 18-fluorode-
oxyglucose uptake in an area consistent with the MRI which was 
Table 1. Levels of baseline and follow-up serum cortisol, ACTH, 
and 24-hour UFC after overnight dexamethasone suppression 
test, low-dose dexamethasone suppression test, and high-dose 
dexamethasone suppression test, and after operation
Variable Cortisol(µg/dL)
UFC
(µg/24 hr)
ACTH
(pg/mL)
Baseline 38.4 1,288.0d) 62.2e)
Midnight 32.0f )
  ODST
    Baseline 38.4 - -
    Follow-upa) 30.0b) - -
  LDDST
    Baseline 30.0 - -
    Follow-upa) 11.9b) - -
  HDDST
    Baseline 30.0 1,288.0 36.4
    Follow-upa) 8.3c) 251.0 12.0
1 Day after operation 1.8 - <1.0
4 Months after operation 8.5 239.4 <1.0
ACTH, adrenocorticotropic hormone; UFC, urine-free cortisol; 
ODST, overnight dexamethasone suppression test; LDDST, low-
dose dexamethasone suppression test; HDDST, high-dose 
dexamethasone suppression test.
a)Cortisol level was followed up at 8 AM the following morning. 
b)Normal reference value is <1.8 µg/dL. c)More than 50% 
suppression from the basal value is positive, and 90% with 
Cushing disease have a positive result. d)Normal reference 
value is 10–34 μg/day, and 4 folds greater than normal can be 
diagnostic for Cushing syndrome. e)If ACTH level is undetectable, 
ACTH-independent Cushing disease is suspected, and if ACTH 
level is greater than 15 pg/mL, then ACTH-dependent Cushing 
disease is suggested. f )If the level is greater than 90 pg/mL, then 
an ectopic ACTH-secreting tumor is suspected, and if the level is 
22–90 pg/mL, then Cushing disease is suggested.
(A) (B) (C) 
Fig. 1. Initial morphology suggesting Cushing syndrome, including moon-shaped face (A), a buffalo hump (B), 
truncal obesity, and abdominal striae (C).
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not suppressed after dexamethasone, thus supporting the MRI 
findings of an adenoma (Fig. 2C, D). An In-111 Octreoscan 
(Mallinckrodt Nuclear Medicine, Maryland Heights, MO, USA) 
showed no evidence of ectopic ACTH-secreting tumor. 
Transsphenoidal surgery was considered the initial treatment 
of choice. As preservation of normal pituitary tissue is directly 
related to surgical success and prognosis2), bilateral IPSS was 
performed by an expert neuroradiologist to determine the 
localization and laterality of ACTH secretion. The maximum 
ratio of ACTH concentrations between the inferior petrosal 
sinus and peripheral vein on the left side after injection of 
desmopressin was remarkably higher than that measured 
on the right side, suggesting left lateralization of  ACTH 
secretion (Table 2). Subsequently, total resection of the tumor 
by a transsphenoidal approach through the left nostril was 
performed. Yellow, slightly solid tissue was identified at the 
medial aspect of the left and lateral areas of the right cavernous 
space. Pathology of the biopsied tissue confirmed a pituitary 
adenoma. Postoperative MRI showed no gross residual tumor, 
and there was no significant complication. Serum ACTH and 
cortisol levels measured on the day after surgery were markedly 
decreased (<1.0 pg/mL and 1.8 µg/dL, respectively), which 
confirmed that the surgery had been successful (Table 1). The 
patient was prescribed a long-term oral glucocorticoid 15 
mg/body surface area, and was discharged. Four months after 
surgery, mild cushingoid features remained, but were much 
improved compared to the initial morphology.   Laboratory data 
showed no evidence of recurrence (Table 1). The patient is now 
tapering oral glucocorticoid (7 mg/body surface area), taking 
oral calcium and vitamin D, and receiving recombinant growth 
hormone therapy after confirming growth hormone deficiency 
on the combined pituitary function test. Long-term follow-
up for linear growth, osteoporosis, adrenal insufficiency, and 
Cushing disease recurrence is required.
Discussion
Cushing syndrome comprises the symptoms and signs 
associated with prolonged exposure to inappropriately elevated 
levels of free plasma glucocorticoids from both endogenous 
and exogenous sources1). Classic features include centripetal 
obesity, moon face, hirsutism, and plethora, but systemic 
(A) (B) 
(C) (D) 
Fig. 2. Preoperative imaging study including magnetic resonance imaging (A, B) and positron 
emission tomography-computed tomography pre- (C) and postdexamethasone injection (D), 
suggesting microadenoma.
Table 2. Levels of ACTH measured during bilateral IPSS after desmopressin injection
ACTH (pg/mL)  0 Min 3 Min 5 Min 10 Min 15 Min
Peripheral 48 218 239 263 233
Rt IPSS (C/P ratio) 55 (1.1) 273 (1.3) 280 (1.2) 262 (1.0) 263 (1.1)
Lt IPSS (C/P ratio) 484 (10.0) 4419 (20.2) 3,223 (13.4) 3,032 (11.5) 2,738 (11.7)
ACTH, adrenocorticotropic hormone; IPSS, inferior petrosal sinus sampling; Rt, right; Lt, left; C/P ratio, central/peripheral ratio.
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involvement is also seen1). Obesity, hypogonadism, psychiatric 
abnormality, myopathy, hypertension, and infections are 
representative clinical manifestations of Cushing syndrome1). 
In childhood, poor linear growth and weight gain are the 
most common manifestations, as in this case. Investigation of 
Cushing syndrome is done in 2 steps. The first is to confirm 
Cushing syndrome clinically and biochemically by checking 
the circadian rhythm of plasma cortisol and UFC excretion, 
and by performing an overnight or low-dose dexamethasone 
suppression test1). The next step is to determine the cause, which 
includes checking levels of plasma ACTH, performing a high-
dose dexamethasone suppression test, IPSS, MRI scanning of 
the pituitary and adrenal glands, scintigraphy, and testing for 
tumor markers1). 
IPSS is the most important test, especially in patients 
who do not present with a definite pituitary lesion. It was 
first performed in 1977 by Corrigan, and the protocol was 
later improved by Landolt through the addition of CRH 
stimulation7). Because CRH is expensive and not widely 
available at present, desmopressin is emerging as an alternative 
to CRH4). Vasopressin is one of the most powerful stimuli of 
ACTH secretion and desmopressin is a synthetic vasopressin 
analog. It binds to pituitary vasopressin type 3 (V3) receptors 
and stimulates ACTH secretion in a pituitary tumor that 
expresses V2 and V3 receptors8). If the central/peripheral ACTH 
ratio determined by IPSS increases by more than two prior 
to administration of desmopressin, and by more than three 
after administration of desmopressin, then Cushing disease 
due to microadenoma is strongly suggested. Studies of the 
efficacy of desmopressin have mostly yielded positive results. 
Deipolyi et al.6) performed 20 cases of IPSS using desmopressin, 
and demonstrated 94.5% sensitivity, comparable with CRH 
stimulation6). Among 36 cases in the literature, IPSS using 
desmopressin had a sensitivity of 95% for Cushing disease, and 
a specificity of 100% for ectopic ACTH secretion7). Current case 
administered demopressin as a stimulant for IPSS, considering 
the wide availability, sensitivity and specifity of desmopressin 
compared with CRH.
However, lateralization by IPSS is controversial. Castinetti 
et al.7) found low sensitivity (50%) in determination of the side 
of the adenoma in 36 cases of IPSS7). In the current case, the 
peak central/peripheral ratio during right IPSS remained at 
0.9–1, whereas the ratio on the left increased to a maximum of 
20, suggesting left lateralization. The operative findings, which 
showed a tumor on the left side, were concordant with these 
results. Therefore, IPSS was thought to be the most reliable 
test to distinguish between Cushing disease and ectopic 
ACTH syndrome, particularly in cases where current imaging 
techniques have limitations. Additionally, IPSS can provide 
more precise information about the localization of the tumor to 
the neurosurgeon for successful resection4).
In our case, there were no serious complications during IPSS, 
such as venous thrombosis, pulmonary embolism, cranial nerve 
palsy, or brainstem vascular damage5). However, desmopressin 
use mandates additional precautions compared to CRH, 
as this agent has a known hemostatic action and promotes 
the release of von Willebrand factor9). As IPSS is an invasive 
technique, further use of desmopressin might require additional 
precautions by specialists who perform the procedure.
In conclusion, IPSS using desmopressin has rarely been 
reported in children. Our case suggests that desmopressin 
use instead of CRH to stimulate ACTH in pediatric patients 
may be safe and effective. IPSS can be a valuable tool not 
only for discriminating between pituitary origin and ectopic 
ACTH-secreting Cushing syndrome, but also for providing 
lateralization of pituitary adenomas.
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